Circulating Inhibitors

Laboratory detection finding characteristic of acquired circulating inhibitors of coagulation is

Target structures against which specific circulating inhibitors are directed are

Clinical outcome primary associated with specific circulating inhibitors is

Most common specific circulating inhibitors observed clinically are

Antibody classes associated with lupus anticoagulant non-specific inhibitors include

Prevalence rate of lupus anticoagulant in systemic lupus erythematosus (SLE) patients is

General PT and APTT screening pattern seen with lupus anticoagulant is

Target structure of lupus anticoagulant antibodies and associated clinical bleeding tendency are

Laboratory tests used to evaluate non-specific inhibitors like lupus anticoagulant include

Examples of non-specific circulating inhibitors in plasma include

Thrombin complex component responsible for activating Protein C in the body is

Target factors inactivated by Activated Protein C (APC) in the anticoagulant pathway are

Role of Protein S in the Protein C anticoagulant system is

Main serine protease inhibitor in the plasma serine protease inhibitor (SERPIN) system is

Enzymes and factors inhibited by Antithrombin (AT) in coagulation include

Definition of fibrinolysis in the coagulation system refers to

Timeline when fibrinolysis initiates after fibrin cross-linking is

Two plasminogen activators released in response to inflammation and coagulation are

Proteins of the fibrinolysis pathway that accumulate on fibrin during clotting are

Primary action of TPA and UPA on fibrin-bound plasminogen hours after clot formation is

Site of synthesis and transport cell type for the zymogen plasminogen are

Enzymatic nature of plasmin and its function on bound fibrin are

Plasma proteins degraded by free plasmin in primary fibrinolysis if uninhibited include

Plasma inhibitor that rapidly binds and inactivates free plasmin in circulation is

Secreting cell source and function of Tissue Plasminogen Activator (TPA) are

Circulating inhibitor bound to TPA in plasma prior to clearance is

Secreting cell sources for Urokinase Plasminogen Activator (UPA) include

Fibrin binding capability and physiologic role of UPA compared to TPA are

Primary role of Plasminogen Activator Inhibitor 1 (PAI-1) in fibrinolysis is

Enzymatic activators inhibited by PAI-1 to prevent plasminogen conversion are

Organ site of synthesis and main role of α2-antiplasmin are

Pharmacologic antifibrinolytic agents that inhibit the proteolytic activity of plasmin are

Site of synthesis and activating complex for Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) are

Functional role of activated TAFI in the fibrinolytic system is

Fibrin degradation product containing D-dimer is generated when

Diffentiation in D-dimer production between fibrin lysis and fibrinogen lysis is

Diagnostic implication of D-dimer presence in plasma is

Combination of FDP/FSP and D-dimer results specific for Pathological Fibrinolysis is

Combination of FDP/FSP and D-dimer results specific for Disseminated Intravascular Coagulation (DIC) is

Condition under which euglobulin proteins precipitate in the Euglobulin Lysis Time test is

Components included in the precipitated euglobulin fraction are

Sample preparation steps prior to redissolving and clotting in Euglobulin Lysis Time are

Typical normal value for Euglobulin Lysis Time is

Diagnostic interpretation when euglobulin clot lysis occurs in less than 2 hours is

Alternative name and location of G proteins in platelet activation are

Two major internal platelet signaling pathways stimulated by G proteins are

Alternative names for the eicosanoid synthesis pathway are

Origin precursor molecule of eicosanoids is

Examples of lipid mediators classified as eicosanoids include

Enzyme activated when collagen, ADP, thrombin, and epinephrine bind platelet membrane receptors is

Substrate cleaved by Phospholipase A2 to release arachidonic acid is

Sequential enzymes acting on arachidonic acid to synthesize TXA2 in platelets are

Intracellular effect of TXA2 on adenylate cyclase and cyclic AMP in platelets is

Organelle from which ionic calcium is released due to reduced cAMP during TXA2 action is

Key difference in eicosanoid pathway enzymes between endothelial cells and platelets is

End product of the eicosanoid pathway in endothelial cells is

Membrane receptor to which prostacyclin binds on the platelet surface is

Effect of prostacyclin on adenylate cyclase, cyclic AMP, and ionic calcium in platelets is

Net effect of intact endothelial cell eicosanoid pathway on platelets is

Enzyme activated directly by G-protein in the IP3-DAG pathway is

Substrate cleaved by Phospholipase C to generate IP3 and DAG is

Primary function of IP3 in the IP3-DAG pathway is

Secondary enzyme that IP3 may activate in platelet signaling is

Enzyme activated by DAG in the IP3-DAG pathway is

Protein phosphorylated by Phosphokinase C to regulate actin microfilament contraction is

Three primary factors exposed or released upon blood vessel injury to initiate hemostasis are

Definition of platelet adhesion is

Subendothelial matrix structure that initiates platelet adhesion upon vessel injury is

Source organelle from which damaged endothelial cells release VWF is

Conformational change of VWF upon binding exposed matrix at the injured site is

Specific subunit portion of platelet GP Ib/IX/V complex that binds unrolled VWF is

Physical nature of the initial VWF-GPIbα interaction is

Enzyme that regulates localized platelet-VWF interactions by digesting unused VWF is

Platelet surface receptor required to bind exposed collagen and halt rolling is

Agonist molecules released internally when collagen binds platelet GP VI receptor are

Platelet surface receptors bound by TXA2 and ADP to increase α2β1 affinity are

Integrin receptor whose affinity for collagen is increased by TXA2 and ADP signaling is

Combined effect of GP Ib/IX/V, GP VI, and α2β1 binding during adhesion is

Inside-out activation target stimulated by TXA2 and ADP on adjacent platelets is

Definition of platelet aggregation is

Thrombin receptors on platelets activated by tissue factor generation are

Specialized platelet phenotype generated by collagen and thrombin co-activation is

Membrane assembly subunits that form functional αIIbβ3 integrin are

Bridge molecules that bind αIIbβ3 receptors to support platelet-to-platelet aggregation are

Morphologic change occurring in thrombocytes during aggregation is

Membrane phospholipid rearrangement occurring on aggregating platelets is

Purpose of phosphatidylserine exposure on the outer platelet membrane is

Ultimate fate of aggregated platelets as cytoplasmic integrity is lost is

Internal structural movement triggering granule compression during platelet secretion is

Phospholipid surface on which tenase and prothrombinase complexes assemble is

Required ion that supports assembly of tenase and prothrombinase on phosphatidylserine is

Key coagulation factors stored in and secreted from α-granules include

Canalicular system through which α-granule and lysosome contents flow during secretion is

Destination route for dense granules during platelet secretion is

Hemostatic functional role of α-granule contents is

Hemostatic functional role of dense granule contents is

In vivo digestive role of platelet lysosomal contents is

Clinical definition of Bleeding Time is

Hemostatic parameters screened using Bleeding Time testing are

Hemostatic system that does NOT affect Bleeding Time results is

Four major physiological/pathological factors that affect Bleeding Time results are

Discontinuation timeframe for Aspirin or aspirin-containing products prior to Bleeding Time is

Discontinuation timeframe for NSAIDs (ibuprofen, tolmetin sodium, naproxen) prior to Bleeding Time is

Puncture site and instrument used in the Duke method for Bleeding Time are

Blotting paper material and time interval specified for Duke method Bleeding Time are

Normal value range for Duke method Bleeding Time is